We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

FER:BMEFerrovial SE Analysis

Data as of 2026-07-19 - not real-time

$63.59

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Ferrovial trades at a **PE of 49.7**, well above the industry average of 30.8, indicating that the market is pricing in strong growth expectations despite modest 5.7% revenue growth. Technicals show the stock hovering just above its **support at $63.09** (current price $63.59) with an **RSI of 35** (oversold) and a **bearish MACD**, suggesting limited upside in the near term. The company delivers a **2.6% dividend yield** but with a **75% payout ratio** and a **debt‑to‑equity of 140**, the sustainability of that payout is questionable. Recent news highlights a Q1 earnings beat driven by toll‑road strength and a new U.S. infrastructure win, yet Citigroup downgraded its outlook to neutral, adding to short‑term uncertainty.
Overall, Ferrovial’s high leverage and premium valuation weigh against its attractive cash‑flow‑linked toll assets and solid dividend. Investors should weigh the near‑term technical weakness and valuation premium against the long‑term benefit of inflation‑linked toll revenues and the company’s strategic focus on U.S. projects.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near technical support with bearish MACD
  • Oversold RSI indicating limited upside
  • Mixed news: earnings beat vs. Citigroup downgrade

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • High valuation relative to peers
  • Elevated leverage and debt‑to‑equity ratio
  • Attractive dividend yield but sustainability concerns

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Stable, inflation‑linked cash flows from U.S. toll roads
  • Strategic shift toward high‑growth urban infrastructure
  • Potential for dividend growth as cash generation improves

Key Metrics & Analysis

Financial Health

Revenue Growth5.70%
Profit Margin9.22%
P/E Ratio49.7
ROE14.32%
ROA2.37%
Debt/Equity140.01
P/B Ratio6.8
Op. Cash Flow$1.9B
Free Cash Flow$321.4M
Industry P/E30.8

Technical Analysis

TrendNeutral
RSI35.4
Support$63.09
Resistance$70.94
MA 20$66.81
MA 50$67.43
MA 200$66.66
MACDBearish
VolumeDecreasing
Fear & Greed Index87.91

Valuation

Target Price$76.76
Upside/Downside20.70%
GradeOvervalued
TypeBlend
Dividend Yield2.60%

Risk Assessment

Beta1.00
Volatility25.31%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.